GlassScriptPhysician profile
Adrianne R Funmaker
NPI 1063965192
$4,807.45
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $626 · 2023: $3,448 · 2024: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,610 · Consulting Fee: $345 · Travel and Lodging: $27.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,610.00 |
| Consulting Fee | $345.00 |
| Travel and Lodging | $27.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $2,517.37 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $399.43 | 2022-2024 | Rexulti, Abilify Asimtufii |
| Abbvie INC. | $383.63 | 2022-2024 | |
| Alkermes, INC. | $296.11 | 2022-2024 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $245.04 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $244.01 | 2022-2024 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.47 | 2022-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $144.27 | 2023-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $129.85 | 2023-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $110.26 | 2022-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $49.31 | 2022-2023 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $34.37 | 2023 | Quviviq |
| Almatica Pharma LLC | $21.97 | 2024 | Loreev Xr |
| Noven Therapeutics, LLC | $16.33 | 2024 | Secuado, Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $14.03 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrianne Funmaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.